Oxygenta Pharmaceutical Limited has announced the book closure dates for its 33rd Annual General Meeting (AGM), which will impact trading in its equity shares on the Bombay Stock Exchange (BSE). The Register of Members and share transfer books will remain closed from August 15, 2026, to August 21, 2026, both days inclusive. This closure is necessary to ascertain the list of shareholders entitled to attend and vote at the meeting, which is scheduled to be held on August 21, 2026, at 10:30 a.m. through Video Conference or Other Audio-Visual Means.

The company notified the BSE of these dates on July 30, 2026, via a submission signed by Executive Director Balasubba Reddy Mamilla. The notice confirms that the meeting will address the businesses transacted during the financial year, with shareholders holding securities either in physical form or in dematerialized form eligible to participate.

Key Dates for Shareholders

Shareholders must note specific deadlines to ensure their voting rights are recognized. The company has fixed Friday, August 14, 2026, as the cut-off date for remote e-voting. This date determines which shareholders are entitled to cast their votes electronically before the physical/virtual meeting takes place.

Regulatory Compliance

The announcement aligns with standard regulatory requirements for public listed entities in India. By closing the books, Oxygenta Pharmaceutical ensures a static shareholder register for the duration of the voting process, preventing changes in ownership that could complicate vote counting. The use of remote e-voting allows shareholders who cannot attend the virtual meeting in real-time to exercise their franchise up to the specified cut-off date.

What This Means for Investors

For investors holding equity shares of Oxygenta Pharmaceutical Limited (ISIN: INE102E01018), the primary implication is a temporary suspension of trading activity from August 15 to August 21, 2026. During this period, shares cannot be bought or sold on the BSE. Investors wishing to participate in the corporate governance process must ensure they hold shares as of the record date determined by the book closure. Those intending to vote remotely must do so by August 14, 2026, to have their votes counted for the resolutions presented at the 33rd AGM.

oxygenta pharmaceutical will hold its 33rd Annual General Meeting on August 21, 2026, to approve material related party transactions (RPTs) worth ₹450 crore with its holding company, Virupaksha Organics Limited (VOL), alongside the regularization of key board appointments. The approvals are essential for maintaining operational synergies and financial support structures within the promoter group during FY 2026-27. The meeting underscores the company’s reliance on VOL for both commercial trade and liquidity, particularly as Oxygenta reported a net loss of ₹1,757.17 lakhs for FY 2025-26 against revenue of ₹11,298.19 lakhs.

The Board of Directors seeks shareholder approval for two primary categories of transactions with VOL, which holds a 56.50% stake in the company. These include commercial transactions for the sale and purchase of goods, capped at ₹250 crore, and financial arrangements involving inter-corporate borrowings and guarantees, capped at ₹200 crore. The resolutions require compliance with Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates shareholder approval for material RPTs exceeding specified thresholds. All transactions are intended to be conducted at arm’s length.

Related Party Transaction Details

The proposed transactions are structured to support the company’s operational continuity and liquidity needs. The aggregate value for commercial transactions is capped at ₹250 crore, while financial facilities are capped at ₹200 crore. The inter-corporate borrowings carry an interest rate of 9% per annum with a tenure of three years. The funds are designated for repaying unsecured loans and clearing outstanding vendor payments. VOL has provided corporate guarantees for these facilities, mitigating risk for the lenders.

Board Appointments and Governance

Shareholders will vote on the regularisation of two additional directors appointed by the Board on May 23, 2026. Amireddy Venkatesu Reddy is proposed for appointment as Whole-Time Director for a term of three years, effective May 23, 2026. His remuneration is set within a pay scale of ₹6,00,000 to ₹8,00,000 per month, subject to the limits prescribed under Schedule V of the Companies Act, 2013. Venkatesu Reddy brings over 26 years of experience in the pharmaceutical industry, including prior association with VOL.

Janardhana Reddy Yeddula is proposed for appointment as an Independent Director for a five-year term, also effective May 23, 2026. He holds a bachelor’s degree in commerce and a diploma in labour laws. Yeddula currently serves as an Independent Director at Virupaksha Organics Limited and Sigachi Industries Limited. His appointment aims to strengthen governance oversight, particularly given the recent change in control following VOL’s acquisition. The AGM also addresses the reappointment of Balasubba Reddy Mamilla, who retires by rotation and continues as Whole-Time Director.

Financial Context and Going Concern

Statutory Auditors M/s. A.M. Reddy & D.R. Reddy have issued an unmodified opinion on the financial statements. However, the auditor’s report highlights a material uncertainty related to going concern due to accumulated losses and negative equity of ₹4,268.68 lakhs. The Board cites continued financial support from VOL and a restructuring plan as mitigating factors. Cost Auditor M/s. PCR & Associates has been appointed for FY 2026-27 with a remuneration of ₹75,000 per annum, pending ratification. The company’s debt-to-equity ratio stands at -2.57 times, reflecting the negative net worth position.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE102E01018/5524a56c-16b5-4c3b-bd6f-468974c8d60c.pdf